Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen
2021 ASCO Annual Meeting
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).
The ASCO Post Staff
Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, discusses updated overall survival data from the phase III PALOMA-3 trial of palbociclib plus fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract 1000).
The ASCO Post Staff
Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance treatment forced the trial to close prematurely (Abstract 7003).
The ASCO Post Staff
Jingxuan Zhao, MPH, of the American Cancer Society, discusses study findings that showed worse long-term survival among low-income patients with cancer who live in states that have not expanded Medicaid eligibility (Abstract 6512).
The ASCO Post Staff
Geoffrey J. Lindeman, MBBS, PhD, of Peter MacCallum Cancer Centre, discusses results from the phase II VERONICA study, which compared venetoclax plus fulvestrant with fulvestrant alone in women with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer who experienced disease recurrence or progression during or after treatment with CDK4/6 inhibitor therapy (Abstract 1004).
The ASCO Post Staff
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses three studies that examined real-world treatment patterns and utilization of advanced therapies in men with metastatic castration-sensitive prostate cancer, which served to highlight the ways in which Black men may be treated differently (Abstracts 5072, 5073, 5704).
